You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

n-803

Showing 1 - 16 of 16
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Glioblastoma Trial (Bevacizumab, PD-L1 t-haNK, N-803)

Not yet recruiting
  • Glioblastoma
  • (no location specified)
Sep 25, 2023

Healthy Subjects Trial in El Segundo (N-803)

Not yet recruiting
  • Healthy Subjects
  • N-803
  • El Segundo, California
    Chan Soon-Shiong Institute for Medicine
Sep 14, 2023

Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS) Trial in Minneapolis (N-803)

Completed
  • Acute Myelogenous Leukemia (AML)
  • Myelodysplastic Syndrome (MDS)
  • N-803
  • Minneapolis, Minnesota
    Masonic Cancer Center at University of Minnesota
Jan 4, 2023

Metastatic Colorectal Cancer Trial run by the National Cancer Institute (NCI) (Retifanlimab, Therapeutic CEA, Brachyury and MUC1

Not yet recruiting
  • Metastatic Colorectal Cancer
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Dec 4, 2023

Castration Resistant Prostate Cancer Trial run by the National Cancer Institute (NCI) (Bintrafusp alfa, N-803, BN-Brachyury)

Not yet recruiting
  • Castration Resistant Prostate Cancer
  • Bintrafusp alfa
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Metastatic Prostate Cancer, Prostate Cancer, Prostate Tumor Trial run by the NCI (M7824, N-803, MVA-BN-Brachyury)

Recruiting
  • Metastatic Prostate Cancer
  • +4 more
  • M7824
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC Trial run by the NCI (N-803, Pembrolizumab, PD-L1 t-haNK)

Recruiting
  • Gastroesophageal Junction (GEJ) Cancers
  • Advanced HNSCC
  • N-803
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2023

NSCLC, Non-Small Cell Lung Carcinoma, NSCLC Trial run by the National Cancer Institute (NCI) (biological, drug, device)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • +3 more
  • Montanide (Registered Trademark) ISA-51 VG Adjuvant
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Bladder Cancer Trial in United States (N-803 and BCG, N-803)

Recruiting
  • Bladder Cancer
  • N-803 and BCG
  • N-803
  • Anchorage, Alaska
  • +31 more
Oct 26, 2022

HIV/AIDS Trial in Bangkok (N-803)

Recruiting
  • HIV/AIDS
  • N-803
  • Bangkok, Thailand
    Thai Red Cross AIDS Research Centre
Oct 4, 2021

NSCLC, Non-small Cell Carcinoma, NSCLC Trial (Ramucirumab, Atezolizumab, N-803)

Withdrawn
  • Non-small Cell Lung Cancer
  • +3 more
  • (no location specified)
Oct 28, 2021

Small Bowel Cancers, Colorectal Cancers Trial run by the NCI (CV301, MSB0011359C, N-803)

Recruiting
  • Small Bowel Cancers
  • Colorectal Cancers
  • CV301
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jul 6, 2022

Advanced Triple Negative Breast Cancer Trial in Newport Beach (N-803, PD-L1 t-haNK, Sacituzumab Govitecan-Hziy)

Active, not recruiting
  • Advanced Triple Negative Breast Cancer
  • N-803
  • +3 more
  • Newport Beach, California
    Hoag Memorial Hospital
Mar 29, 2022

Triple Negative Breast Cancer Trial in El Segundo (drug, biological, procedure)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Aldoxorubicin HCl
  • +17 more
  • El Segundo, California
    Chan Soon-Shiong Institute for Medicine
Mar 28, 2022

Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent Trial in El Segundo (biological, drug, procedure)

Withdrawn
  • Hepatocellular Carcinoma Non-resectable
  • Hepatocellular Carcinoma Recurrent
  • ETBX-011
  • +17 more
  • El Segundo, California
    Chan Soon-Shiong Institute for Medicine
Mar 17, 2021

Squamous Cell Carcinoma Trial in El Segundo (drug, biological, procedure)

Unknown status
  • Squamous Cell Carcinoma
  • Aldoxorubicin HCl
  • +20 more
  • El Segundo, California
    Chan Soon-Shiong Institute for Medicine
Aug 10, 2020